新一代疫苗 2679条(本栏目收费,不能显示细节,电话15274084725)
Societal issues for vaccine industry immunization access to dual track,88 88
intellectual property (IP),88 88
technology transfers,88 88
vaccines rception of,89 89
Sortase attachment sites,15 15
South Asian Association for Regional Cooperation (SAARC) ,156 156
live attenuated vaccine,865,868 868
other vaccine strategies,868 868
Tumor-associated macrophages (TAM) ,936,937 937
Tumor cells vaccines comprised of,329,330 330
Ty2 attenuating strategies,498,499 499
enteric-coated formulation,498 498
‘‘liquid suspension’’ formulation of,498 498
protection correlation of,498 498
reactogenicity in adults and children,497,498 498
541Ty and 543Ty strains,499 499
Type 1 cytokine interferon (IFN)-g,238 238
SPA-TT phase I and phase II clinical trials of,493 493
Split influenza vaccine,327 327
St. Louis encephalitis (SLE) ,557,562 562
Standardization activities of ECBS,122 122
Standard Membrane Feeding Assay (SMFA),757,758 758
Staph enterotoxin,363 363
Staphylococcal toxic shock syndrome,729 729